Table 3 Kaplan–Meier analysis for overall survival rate of patients with gliomas
Characteristics | Mean survival time ± SE | 95% Confidence interval (months) | P values |
|---|---|---|---|
Age (years) | |||
<41 | 49.8 ± 5.4 | 39.2-60.4 | 0.055 |
≥41 | 35.7 ± 4.5 | 26.8-44.5 | |
Gender | |||
Male | 39.2 ± 4.6 | 30.1-48.2 | 0.086 |
Female | 46.2 ±4.3 | 37.8-54.6 | |
Histological grade | |||
Low-grade (WHOI-II) | 60.7 ±4.2 | 52.5-69.0 | <0.01 |
High-grade (WHO III-IV) | 17.3 ±1.7 | 14.0-20.7 | |
Tumor recurrence | |||
No | 61.8 ±1.1 | 59.6-63.9 | <0.01 |
Yes | 33.1 ± 3.7 | 25.9-40.3 | |
Cygb expression | |||
Low expression (<39%) | 23.8 ±3.1 | 17.8-29.8 | <0.01 |
High expression (≥39%) | 62.4 ±4.8 | 53.0-71.7 | |
PI3K expression | |||
Low expression (<20%) | 56.5 ± 5.1 | 46.4-66.5 | <0.01 |
High expression (≧%) | 29.2 ± 4.2 | 20.9-37.5 | |
p-Akt expression | |||
Low expression (<21%) | 55.4 ± 5.1 | 45.3-65.4 | <0.01 |
High expression (≧20%) | 29.6 ± 4.3 | 21.2-38.1 | |
IL-6 expression | |||
Low expression(<35%) | 45.9 ± 5.2 | 35.7-56.2 | 0.157 |
High expression (≧35%) | 40.1 ± 5.0 | 30.3-49.8 | |
TNFα expression | |||
Low expression (<30%) | 62.9 ± 4.6 | 33.8-51.9 | 0.569 |
High expression (≧30%) | 44.2 ± 5.3 | 33.7-54.6 | |
VEGF expression | |||
Low expression (<56%) | 50.1 ± 5.2 | 39.9-60.4 | 0.023 |
High expression (≧56%) | 34.0 ± 3.6 | 26.9-41.2 |